What's in Shanghai Miracogen Inc.'s pipeline?

Shanghai Miracogen Inc. has 11 drugs in our index: 0 marketed, 0 filed, 9 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Shanghai Miracogen Inc.'s portfolio?

Top competitors by shared drug class: Hoffmann-La Roche, Allergan, BioNTech SE, Amgen, AstraZeneca.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/shanghai-miracogen-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Shanghai Miracogen Inc. — Portfolio Competitive Intelligence Brief

Shanghai Miracogen Inc. pipeline: 0 marketed, 0 filed, 9 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 9 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Cetuximab injection	Cetuximab injection	phase 3	EGFR inhibitor monoclonal antibody	EGFR (Epidermal Growth Factor Receptor)	Oncology
Pemetrexed Disodium Injection	Pemetrexed Disodium Injection	phase 3	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase	Oncology
MRG004A plus best supportive care	MRG004A plus best supportive care	phase 3	Bispecific antibody		Oncology
MRG003 + Pucotenlimab	MRG003 + Pucotenlimab	phase 3	Bispecific antibody (MRG003) + PD-L1 inhibitor (Pucotenlimab)	PD-L1, 4-1BB (MRG003); PD-L1 (Pucotenlimab)	Oncology
MRG002	MRG002	phase 3	Bispecific antibody		Oncology
MRG003	MRG003	phase 3	Bispecific antibody		Oncology
Trastuzumab Emtansine for Injection	Trastuzumab Emtansine for Injection	phase 3	HER2-targeting antibody-drug conjugate	HER2	Oncology
Gemcitabine, Docetaxel, or Capecitabine	Gemcitabine, Docetaxel, or Capecitabine	phase 3	Chemotherapy combination (nucleoside analog, taxane, fluoropyrimidine)		Oncology
Placebo plus best supportive care	Placebo plus best supportive care	phase 3

Therapeutic area mix

Oncology · 8

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Hoffmann-La Roche · 2 shared drug classes
Allergan · 1 shared drug class
BioNTech SE · 1 shared drug class
Amgen · 1 shared drug class
AstraZeneca · 1 shared drug class
Atom Therapeutics Co., Ltd · 1 shared drug class
Allist Pharmaceuticals, Inc. · 1 shared drug class
Allakos Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shanghai Miracogen Inc.:

Cite this brief

Drug Landscape (2026). Shanghai Miracogen Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-miracogen-inc. Accessed 2026-05-16.